Fatty Liver Disease
Metabolic·MeSH: Non-alcoholic Fatty Liver Disease
Prevalence
25000.0 / 100K
Incidence
2000.0 / 100K/yr
8 drugs in development·7 companies·1 clinical trial
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| tvb-2640 | Sagimet Biosciences Inc. (SGMT) |
Phase 1(1)
| Drug | Company |
|---|---|
| nnc4005-001 | Novo Nordisk A/S (NVO) |
Preclinical(3)
Unknown(1)
| Drug | Company |
|---|---|
| legalon | Mylan II B.V. (MYL) |
Compare drugs
Frequently asked questions
How many drugs are in development for Fatty Liver Disease?
BioSniper tracks 8 drugs in development for Fatty Liver Disease across 7 companies.
How many clinical trials target Fatty Liver Disease?
There are 1 clinical trial targeting Fatty Liver Disease tracked by BioSniper.
What is the prevalence of Fatty Liver Disease?
The estimated prevalence of Fatty Liver Disease is approximately 25000.0 per 100,000 population.
Deep-dive into Fatty Liver Disease
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis